M. Honma, M. Nakada / Tetrahedron Letters 44 (2003) 9007–9011
9011
References
1998, 98, 911–935; (c) Padwa, A.; Krumpe, K. E. Tetra-
hedron 1992, 48, 5385–5453; (d) Padwa, A.; Hornbuckle,
S. F. Chem. Rev. 1991, 91, 263–309; (e) Adams, J.; Spero,
D. M. Tetrahedron 1991, 47, 1765–1808; (f) Doyle, M. P.
Chem. Rev. 1986, 86, 919–939.
1. Honma, M.; Sawada, T.; Fujisawa, Y.; Utsugi, M.;
Watanabe, H.; Umino, A.; Matsumura, T.; Hagihara, T.;
Takano, M.; Nakada, M. J. Am. Chem. Soc. 2003, 125,
2860–2861.
10. Since the reaction of 7 was sluggish as previously
reported, the IMCP reaction of the mesityl sulfones cor-
responding to 19a and 19b was not examined.
11. Zutterman, F.; Mungheer, D. W. R.; Clercq, P. D.;
Vanderwalle, M. Tetrahedron 1979, 35, 2389–2396.
12. (a) Dess, D. B.; Martin, J. C. J. Org. Chem. 1991, 113,
7277–7287; (b) Frigerio, M.; Santagostino, M.; Sputore,
S. J. Org. Chem. 1999, 64, 4537–4538.
13. Ee was determined by HPLC (254 nm); 20a: Daicel
Chiral Cell OD-H 0.46 cm f×25 cm; hexane/iso-
propanol=9/1; flow rate=0.5 mL/min; retention time:
12.2 min for ent-20a, 15.2 min for 20a. 20b: Daicel Chiral
Cell OD-H 0.46 cm f×25 cm; hexane/isopropanol=9/1;
flow rate=0.5 mL/min; retention time: 23.1 min for
ent-20b, 25.0 min for 20b.
2. For the preparation of sulfones, see Ref. 1.
3. Ee was determined by HPLC (254 nm); 9a: [h]2D1 −97.4 (c
1.27, CHCl3, 99% ee); Daicel Chiral Cell OD-H 0.46 cm
f×25 cm; hexane/isopropanol=3/1; flow rate=0.5 mL/
min; retention time: 22.8 min for ent-9a, 25.0 min for 9a.
9b: [h]2D3 −139.8 (c 0.98, CHCl3, >99% ee); Daicel Chiral
Cell AS-H 0.46 cm f×25 cm; hexane/isopropanol=3/1;
flow rate=0.5 mL/min; retention time: 38.4 min for 9b,
48.9 min for ent-9b. 9c: [h]2D8 +30.3 (c 1.11, CHCl3,
>99.5% ee); Daicel Chiral Cell AS-H 0.46 cm f×25 cm;
hexane/isopropanol=3/1; flow rate=0.5 mL/min; reten-
tion time: 22.5 min for 9c, 25.9 min for ent-9c. 9d: [h]D22
−191.6 (c 1.03, CHCl3, >99.5% ee); Daicel Chiral Cell
AS-H 0.46 cm f×25 cm; hexane/isopropanol=3/1; flow
rate=0.5 mL/min; retention time: 13.1 min for ent-9d,
16.2 min for 9d.
14. Structure of some by-products was not fully character-
ized.
4. 10a: IR(KBr): 2932, 1748, 1448, 1308, 1150, 1080, 824
15. TBS ether 20a was desilylated by TBAF (quant.), and the
resultant alcohol was converted with p-bromobenzoyl
chloride and pyridine to the crystalline p-bromobenzoate
(93%).
cm−1 1H NMR (400 MHz, CDCl3): l=7.88 (d, J=7.8
;
Hz, 2H), 7.68 (t, J=7.3 Hz, 1H), 7.58 (dd, J=7.8, 7.3
Hz, 2H), 5.88 (ddd, J=17.1, 10.5, 6.3 Hz, 1H), 5.13 (d,
J=17.1 Hz, 1H), 5.11 (d, J=10.5 Hz, 1H), 3.59–3.54 (m,
2H), 2.51–2.32 (m, 3H), 1.82–1.71 (m, 1H); 13C NMR
(100 MHz, CDCl3): l=205.8, 138.0, 137.7, 134.1, 129.0,
129.0, 116.1, 73.9, 41.3, 38.4, 26.3; HRMS (FAB): m/z
calcd for C13H14O3SH+ 251.0742, found 251.0770. 10a–d
were obtained as a single diastereomer. The relative
configuration of 10a–d is surmised to be trans on the
basis of their thermodynamic stability. Ee of 10a–d was
not determined.
16. 20a: [h]2D5 +80.9 (c 0.11, CHCl3, 96% ee); IR(KBr): 2956,
2932, 2896, 2860, 1708, 1448, 1310, 1286, 1258, 1180,
1152, 1118, 1086, 840, 778, 756 cm−1 1H NMR (400
;
MHz, CDCl3): l=7.85 (d, J=8.1 Hz, 2H), 7.64 (t, J=7.3
Hz, 1H), 7.53 (dd, J=8.1, 7.3 Hz, 2H), 5.63 (ddd, J=
10.5, 3.4, 2.4 Hz, 1H), 5.24 (d, J=10.5 Hz, 1H), 3.64 (d,
J=9.5 Hz, 1H), 3.62 (d, J=9.5 Hz, 1H), 2.65 (d, J=9.8
Hz, 1H), 2.50–2.35 (m, 1H), 2.25–2.10 (m, 3H), 2.07–1.95
(m, 2H), 1.60–1.50 (m, 1H), 0.93 (s, 9H), 0.09 (s, 6H); 13C
NMR (100 MHz, CDCl3): l=201.3, 139.4, 133.6, 128.8,
128.7, 128.3, 126.3, 69.9, 48.4, 36.2, 35.0, 31.3, 27.0, 25.9,
22.4, 19.8, 18.4, −5.3; HRMS (FAB): m/z calcd for
5. Also examined catalyst was CuI, but many unidentified
products formed.
6. The product was obtained as a complex mixture when
Et2O, DMF, or DMSO was used as the solvent.
7. Other examples using achiral ligand 1e (entries 17, 22 and
27) show no improvement of the by-product formation
and yield.
C23H32O4SSiH+ 433.1869, found 433.1869. 20b: [h]3D7
+
130.7 (c 0.64, CHCl3, 95% ee); IR(KBr): 2864, 1706,
1
1448, 1310, 1288, 1182, 1152, 1086 cm−1; H NMR (400
MHz, CDCl3): l=7.83 (d, J=8.3 Hz, 2H), 7.62 (t, J=7.3
Hz, 1H), 7.48 (dd, J=8.3, 7.3 Hz, 2H), 7.45–7.30 (m,
5H), 5.68 (ddd, J=10.3, 3.4, 2.4 Hz, 1H), 5.30 (d, J=10.3
Hz, 1H), 4.62 (d, J=12.2 Hz, 1H), 4.58 (d, J=12.2 Hz,
1H), 3.53 (d, J=8.8 Hz, 1H), 3.50 (d, J=8.8 Hz, 1H),
2.75 (d, J=9.8 Hz, 1H), 2.52–2.44 (m, 1H), 2.26 (dd,
J=8.3, 7.3 Hz, 1H), 2.17–2.12 (m, 2H), 2.06–1.95 (m,
2H), 1.60–1.54 (m, 1H); 13C NMR (100 MHz, CDCl3):
l=201.1, 139.3, 137.9, 133.6, 128.8, 128.7, 128.4, 128.2,
127.7, 127.6, 126.5, 77.0, 73.5, 48.6, 36.0, 33.9, 31.8, 27.6,
22.7, 19.7; HRMS (FAB): m/z calcd for C24H24O4SH+
409.1473, found 409.1456. 20b (from 20a): [h]3D4 +130.7 (c
0.77, CHCl3, 95% ee).
8. These chiral building blocks would be useful for the total
synthesis of the natural products possessing a hydroxy
group at C-19 such as oubain, which has been used for
more than two centuries in the clinical treatment of
congestive heart failure, and bufadienolides, which
exhibit potent antitumor activity. For the structure of
oubain, see: Arnaud, M. Compt. Rend. Acad. 1888, 107,
1011. For the structure of recently isolated bufadienolides
possessing a formyl group at C-19, see: Watanabe, K.;
Mimaki, Y.; Sakagami, H.; Sashida, Y. J. Nat. Prod.
2003, 66, 236–241.
9. Reviews: (a) Padwa, A. J. Organomet. Chem. 2001, 617–
618, 3–16.; (b) Doyle, M. P.; Forbes, D. C. Chem. Rev.